GLP-1 Side Effects by Drug: Label Rates vs Placebo (Table
Nausea is the most common GLP-1 side effect in every label: from 18% of people on Mounjaro to 44% on Wegovy at the highest dose. Each row below is one label trial, drug against placebo.
- Medicines
- 10
- Rows
- 117
- Source
- FDA labels, section 6.1
| Medicine | Side effect | On the medicine (highest dose) | On placebo | Who was studied |
|---|---|---|---|---|
 Ozempic | Nausea | 20.3% 0.5 mg 15.8%, 1 mg 20.3% | 6.1% | Adults with type 2 diabetes |
| Ozempic | Vomiting | 9.2% 0.5 mg 5%, 1 mg 9.2% | 2.3% | Adults with type 2 diabetes |
| Ozempic | Diarrhea | 8.8% 0.5 mg 8.5%, 1 mg 8.8% | 1.9% | Adults with type 2 diabetes |
| Ozempic | Abdominal pain | 7.3% 0.5 mg 7.3%, 1 mg 5.7% | 4.6% | Adults with type 2 diabetes |
| Ozempic | Constipation | 5% 0.5 mg 5%, 1 mg 3.1% | 1.5% | Adults with type 2 diabetes |
 Wegovy | Nausea | 44% | 16% | Adults with obesity or overweight (weight management) |
| Wegovy | Diarrhea | 30% | 16% | Adults with obesity or overweight (weight management) |
| Wegovy | Vomiting | 24% | 6% | Adults with obesity or overweight (weight management) |
| Wegovy | Constipation | 24% | 11% | Adults with obesity or overweight (weight management) |
| Wegovy | Abdominal Pain | 20% | 10% | Adults with obesity or overweight (weight management) |
| Wegovy | Headache | 14% | 10% | Adults with obesity or overweight (weight management) |
| Wegovy | Fatigue | 11% | 5% | Adults with obesity or overweight (weight management) |
| Wegovy | Dyspepsia | 9% | 3% | Adults with obesity or overweight (weight management) |
| Wegovy | Dizziness | 8% | 4% | Adults with obesity or overweight (weight management) |
| Wegovy | Abdominal Distension | 7% | 5% | Adults with obesity or overweight (weight management) |
| Wegovy | Eructation | 7% | Not listed | Adults with obesity or overweight (weight management) |
| Wegovy | Hypoglycemia in T2DM | 6% | 2% | Adults with obesity or overweight (weight management) |
| Wegovy | Flatulence | 6% | 4% | Adults with obesity or overweight (weight management) |
| Wegovy | Gastroenteritis | 6% | 4% | Adults with obesity or overweight (weight management) |
| Wegovy | Gastroesophageal Reflux Disease | 5% | 3% | Adults with obesity or overweight (weight management) |
| Wegovy | Gastritis | 4% | 1% | Adults with obesity or overweight (weight management) |
| Wegovy | Gastroenteritis Viral | 4% | 3% | Adults with obesity or overweight (weight management) |
| Wegovy | Hair Loss | 3% | 1% | Adults with obesity or overweight (weight management) |
| Wegovy | Dysesthesia | 2% | 1% | Adults with obesity or overweight (weight management) |
 Rybelsus | Nausea | 20% 7 mg 11%, 14 mg 20% | 6% | Adults with type 2 diabetes |
| Rybelsus | Abdominal Pain | 11% 7 mg 10%, 14 mg 11% | 4% | Adults with type 2 diabetes |
| Rybelsus | Diarrhea | 10% 7 mg 9%, 14 mg 10% | 4% | Adults with type 2 diabetes |
| Rybelsus | Decreased appetite | 9% 7 mg 6%, 14 mg 9% | 1% | Adults with type 2 diabetes |
| Rybelsus | Vomiting | 8% 7 mg 6%, 14 mg 8% | 3% | Adults with type 2 diabetes |
| Rybelsus | Constipation | 6% 7 mg 6%, 14 mg 5% | 2% | Adults with type 2 diabetes |
 Mounjaro | Nausea | 18% 5 mg 12%, 10 mg 15%, 15 mg 18% | 4% | Adults with type 2 diabetes |
| Mounjaro | Diarrhea | 17% 5 mg 12%, 10 mg 13%, 15 mg 17% | 9% | Adults with type 2 diabetes |
| Mounjaro | Decreased Appetite | 11% 5 mg 5%, 10 mg 10%, 15 mg 11% | 1% | Adults with type 2 diabetes |
| Mounjaro | Vomiting | 9% 5 mg 5%, 10 mg 5%, 15 mg 9% | 2% | Adults with type 2 diabetes |
| Mounjaro | Constipation | 7% 5 mg 6%, 10 mg 6%, 15 mg 7% | 1% | Adults with type 2 diabetes |
| Mounjaro | Dyspepsia | 8% 5 mg 8%, 10 mg 8%, 15 mg 5% | 3% | Adults with type 2 diabetes |
| Mounjaro | Abdominal Pain | 6% 5 mg 6%, 10 mg 5%, 15 mg 5% | 4% | Adults with type 2 diabetes |
 Zepbound | Nausea | 29% 5 mg 25%, 10 mg 29%, 15 mg 28% | 8% | Adults with obesity or overweight (weight management) |
| Zepbound | Diarrhea | 23% 5 mg 19%, 10 mg 21%, 15 mg 23% | 8% | Adults with obesity or overweight (weight management) |
| Zepbound | Vomiting | 13% 5 mg 8%, 10 mg 11%, 15 mg 13% | 2% | Adults with obesity or overweight (weight management) |
| Zepbound | Constipation | 17% 5 mg 17%, 10 mg 14%, 15 mg 11% | 5% | Adults with obesity or overweight (weight management) |
| Zepbound | Abdominal Pain | 10% 5 mg 9%, 10 mg 9%, 15 mg 10% | 5% | Adults with obesity or overweight (weight management) |
| Zepbound | Dyspepsia | 10% 5 mg 9%, 10 mg 9%, 15 mg 10% | 4% | Adults with obesity or overweight (weight management) |
| Zepbound | Injection Site Reactions | 8% 5 mg 6%, 10 mg 8%, 15 mg 8% | 2% | Adults with obesity or overweight (weight management) |
| Zepbound | Fatigue | 7% 5 mg 5%, 10 mg 6%, 15 mg 7% | 3% | Adults with obesity or overweight (weight management) |
| Zepbound | Hypersensitivity Reactions | 5% 5 mg 5%, 10 mg 5%, 15 mg 5% | 3% | Adults with obesity or overweight (weight management) |
| Zepbound | Eructation | 5% 5 mg 4%, 10 mg 5%, 15 mg 5% | 1% | Adults with obesity or overweight (weight management) |
| Zepbound | Hair Loss | 5% 5 mg 5%, 10 mg 4%, 15 mg 5% | 1% | Adults with obesity or overweight (weight management) |
| Zepbound | Gastroesophageal Reflux Disease | 5% 5 mg 4%, 10 mg 4%, 15 mg 5% | 2% | Adults with obesity or overweight (weight management) |
| Zepbound | Flatulence | 4% 5 mg 3%, 10 mg 3%, 15 mg 4% | 2% | Adults with obesity or overweight (weight management) |
| Zepbound | Abdominal Distension | 4% 5 mg 3%, 10 mg 3%, 15 mg 4% | 2% | Adults with obesity or overweight (weight management) |
| Zepbound | Dizziness | 5% 5 mg 4%, 10 mg 5%, 15 mg 4% | 2% | Adults with obesity or overweight (weight management) |
| Zepbound | Hypotension | 2% 5 mg 1%, 10 mg 1%, 15 mg 2% | 0% | Adults with obesity or overweight (weight management) |
 Foundayo | Nausea | 35% 5.5 mg 26%, 9 mg 34%, 17.2 mg 35% | 10% | Adults with obesity or overweight (weight management) |
| Foundayo | Constipation | 27% 5.5 mg 20%, 9 mg 27%, 17.2 mg 24% | 9% | Adults with obesity or overweight (weight management) |
| Foundayo | Diarrhea | 25% 5.5 mg 21%, 9 mg 23%, 17.2 mg 25% | 11% | Adults with obesity or overweight (weight management) |
| Foundayo | Vomiting | 24% 5.5 mg 13%, 9 mg 21%, 17.2 mg 24% | 4% | Adults with obesity or overweight (weight management) |
| Foundayo | Dyspepsia | 16% 5.5 mg 12%, 9 mg 16%, 17.2 mg 13% | 4% | Adults with obesity or overweight (weight management) |
| Foundayo | Abdominal pain | 14% 5.5 mg 13%, 9 mg 14%, 17.2 mg 14% | 7% | Adults with obesity or overweight (weight management) |
| Foundayo | Headache | 9% 5.5 mg 8%, 9 mg 9%, 17.2 mg 9% | 7% | Adults with obesity or overweight (weight management) |
| Foundayo | Abdominal distension | 9% 5.5 mg 7%, 9 mg 9%, 17.2 mg 8% | 3% | Adults with obesity or overweight (weight management) |
| Foundayo | Fatigue | 9% 5.5 mg 6%, 9 mg 7%, 17.2 mg 9% | 4% | Adults with obesity or overweight (weight management) |
| Foundayo | Eructation | 8% 5.5 mg 6%, 9 mg 8%, 17.2 mg 8% | 1% | Adults with obesity or overweight (weight management) |
| Foundayo | Gastroesophageal reflux disease | 7% 5.5 mg 6%, 9 mg 6%, 17.2 mg 7% | 2% | Adults with obesity or overweight (weight management) |
| Foundayo | Flatulence | 6% 5.5 mg 5%, 9 mg 6%, 17.2 mg 6% | 2% | Adults with obesity or overweight (weight management) |
| Foundayo | Hair loss | 5% 5.5 mg 4%, 9 mg 4%, 17.2 mg 5% | 2% | Adults with obesity or overweight (weight management) |
 Trulicity | Nausea | 21.1% 0.75 mg 12.4%, 1.5 mg 21.1% | 5.3% | Adults with type 2 diabetes |
| Trulicity | Diarrhea | 12.6% 0.75 mg 8.9%, 1.5 mg 12.6% | 6.7% | Adults with type 2 diabetes |
| Trulicity | Vomiting | 12.7% 0.75 mg 6%, 1.5 mg 12.7% | 2.3% | Adults with type 2 diabetes |
| Trulicity | Abdominal Pain | 9.4% 0.75 mg 6.5%, 1.5 mg 9.4% | 4.9% | Adults with type 2 diabetes |
| Trulicity | Decreased Appetite | 8.6% 0.75 mg 4.9%, 1.5 mg 8.6% | 1.6% | Adults with type 2 diabetes |
| Trulicity | Dyspepsia | 5.8% 0.75 mg 4.1%, 1.5 mg 5.8% | 2.3% | Adults with type 2 diabetes |
| Trulicity | Fatigue | 5.6% 0.75 mg 4.2%, 1.5 mg 5.6% | 2.6% | Adults with type 2 diabetes |
 Saxenda | Nausea | 39.3% | 13.8% | Adults with obesity or overweight (weight management) |
| Saxenda | Diarrhea | 20.9% | 9.9% | Adults with obesity or overweight (weight management) |
| Saxenda | Constipation | 19.4% | 8.5% | Adults with obesity or overweight (weight management) |
| Saxenda | Vomiting | 15.7% | 3.9% | Adults with obesity or overweight (weight management) |
| Saxenda | Injection Site Reaction | 13.9% | 10.5% | Adults with obesity or overweight (weight management) |
| Saxenda | Headache | 13.6% | 12.6% | Adults with obesity or overweight (weight management) |
| Saxenda | Hypoglycemia in T2DM | 12.6% | 6.6% | Adults with obesity or overweight (weight management) |
| Saxenda | Dyspepsia | 9.6% | 2.7% | Adults with obesity or overweight (weight management) |
| Saxenda | Fatigue | 7.5% | 4.6% | Adults with obesity or overweight (weight management) |
| Saxenda | Dizziness | 6.9% | 5% | Adults with obesity or overweight (weight management) |
| Saxenda | Abdominal Pain | 5.4% | 3.1% | Adults with obesity or overweight (weight management) |
| Saxenda | Increased Lipase | 5.3% | 2.2% | Adults with obesity or overweight (weight management) |
| Saxenda | Upper Abdominal Pain | 5.1% | 2.7% | Adults with obesity or overweight (weight management) |
| Saxenda | Gastroenteritis | 4.7% | 3.2% | Adults with obesity or overweight (weight management) |
| Saxenda | Gastroesophageal Reflux Disease | 4.7% | 1.7% | Adults with obesity or overweight (weight management) |
| Saxenda | Abdominal Distension | 4.5% | 3% | Adults with obesity or overweight (weight management) |
| Saxenda | Eructation | 4.5% | 0.2% | Adults with obesity or overweight (weight management) |
| Saxenda | Urinary Tract Infection | 4.3% | 3.1% | Adults with obesity or overweight (weight management) |
| Saxenda | Flatulence | 4% | 2.5% | Adults with obesity or overweight (weight management) |
| Saxenda | Viral Gastroenteritis | 2.8% | 1.6% | Adults with obesity or overweight (weight management) |
| Saxenda | Insomnia | 2.4% | 1.7% | Adults with obesity or overweight (weight management) |
| Saxenda | Dry Mouth | 2.3% | 1% | Adults with obesity or overweight (weight management) |
| Saxenda | Asthenia | 2.1% | 0.8% | Adults with obesity or overweight (weight management) |
| Saxenda | Anxiety | 2% | 1.6% | Adults with obesity or overweight (weight management) |
 Victoza | Nausea | 20% 1.2 mg 18%, 1.8 mg 20% | 5% | Adults with type 2 diabetes |
| Victoza | Diarrhea | 12% 1.2 mg 10%, 1.8 mg 12% | 4% | Adults with type 2 diabetes |
| Victoza | Headache | 11% 1.2 mg 11%, 1.8 mg 10% | 7% | Adults with type 2 diabetes |
| Victoza | Nasopharyngitis | 10% 1.2 mg 9%, 1.8 mg 10% | 8% | Adults with type 2 diabetes |
| Victoza | Vomiting | 9% 1.2 mg 6%, 1.8 mg 9% | 2% | Adults with type 2 diabetes |
| Victoza | Decreased appetite | 10% 1.2 mg 10%, 1.8 mg 9% | 1% | Adults with type 2 diabetes |
| Victoza | Dyspepsia | 7% 1.2 mg 4%, 1.8 mg 7% | 1% | Adults with type 2 diabetes |
| Victoza | Upper Respiratory Tract Infection | 7% 1.2 mg 7%, 1.8 mg 6% | 6% | Adults with type 2 diabetes |
| Victoza | Constipation | 5% 1.2 mg 5%, 1.8 mg 5% | 1% | Adults with type 2 diabetes |
| Victoza | Back Pain | 5% 1.2 mg 4%, 1.8 mg 5% | 3% | Adults with type 2 diabetes |
| Byetta | Nausea | 44% | 18% | Adults with type 2 diabetes |
| Byetta | Vomiting | 13% | 4% | Adults with type 2 diabetes |
| Byetta | Diarrhea | 13% | 6% | Adults with type 2 diabetes |
| Byetta | Feeling Jittery | 9% | 4% | Adults with type 2 diabetes |
| Byetta | Dizziness | 9% | 6% | Adults with type 2 diabetes |
| Byetta | Headache | 9% | 6% | Adults with type 2 diabetes |
| Byetta | Dyspepsia | 6% | 3% | Adults with type 2 diabetes |
| Byetta | Asthenia | 4% | 2% | Adults with type 2 diabetes |
| Byetta | Gastroesophageal Reflux Disease | 3% | 1% | Adults with type 2 diabetes |
| Byetta | Hyperhidrosis | 3% | 1% | Adults with type 2 diabetes |
Download every row as CSV (217 rows)
Weight loss and half-life, in brief
In days, half-life is how long the body takes to clear half a dose. Each FDA label gives this in section 12.3.
Percentage of body weight. Because trials, doses, and lengths differed, compare each trial with the placebo on its page.
How many stopped because of side effects?
Read the details of one side effect
- Ozempic Side Effects
- GLP-1 Side Effects
- Mounjaro Side Effects
- Zepbound Side Effects by Frequency
- Wegovy Side Effects
- Tirzepatide Side Effects
- Semaglutide Side Effects by Frequency
- Trulicity Side Effects
- Ozempic Long-Term Side Effects
- Rybelsus Side Effects by Frequency
- GLP-1 Long-Term Side Effects
- Tirzepatide Long-Term Side Effects
- Ozempic Side Effects in Women
- Mounjaro Long-Term Side Effects
- Victoza Side Effects
- Foundayo Side Effects by Dose
- Wegovy Long-Term Side Effects
- Liraglutide Side Effects
- Saxenda Side Effects
- Orforglipron Side Effects
- How Long Do Ozempic Side Effects Last? Timeline by Symptom
- Survodutide Side Effects
- Ozempic Side Effects in Non Diabetics
- Rybelsus Long-Term Side Effects